Evidence map›Paper›PMID 40665565›Full record

ArticleJournal of cellular and molecular medicine2025

SERPINB6 Promotes Epithelial-Mesenchymal Transition via PI3K/AKT/mTOR Signalling Pathway in Glioma.

Ding Wang, Haiyang Wang, Wenhao Zheng, Heng Wang, Wenhua Yu, Quan Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ding WangDepartment of Neurosurgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People's Republic of China.
Haiyang WangDepartment of Neurosurgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People's Republic of China.
Wenhao ZhengDepartment of Neurosurgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People's Republic of China.
Heng WangDepartment of Neurosurgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People's Republic of China.
Wenhua YuDepartment of Neurosurgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People's Republic of China.
Quan DuDepartment of Neurosurgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People's Republic of China.ORCID 0000-0003-0989-6571

Funding

Joint Funds of the Zhejiang Provincial Natural Science Foundation of China LHZY24H090004Science and Technology Development Project of Hangzhou 2020ZDSJ0900Science and Technology Development Project of Hangzhou 20211231Y025Science and Technology Development Project of Hangzhou 202204B11Zhejiang medical and healthy technology project 2023KY950
6 · The paper itself

Abstract

Glioma is the most common and highly invasive type of brain cancer in the central nervous system, characterised by a low survival rate and poor prognosis. The role of SERPINB6 has been proven crucial in programmed necrosis and cancer progression. However, its role in glioma has not yet been clearly defined. This study utilised bioinformatics methods and in vitro and in vivo experiments to assess the expression, function and potential mechanisms of SERPINB6 in the development of glioma. Our study found that SERPINB6 plays a carcinogenic role in glioma, and its expression level is significantly negatively correlated with patient prognosis. The study also found that inhibiting SERPINB6 expression can hinder the epithelial-mesenchymal transition (EMT) of glioma cells. Conversely, overexpression of SERPINB6 aggravated the occurrence of EMT. Particularly noteworthy is the mechanism of SERPINB6 in promoting EMT in glioma, which is achieved through the activation of the PI3K/AKT/mTOR signalling pathway. By activating the PI3K/AKT/mTOR pathway, SERPINB6 promotes EMT in glioma, demonstrating its great potential as a new target for glioma treatment.

Indexed as

Brain NeoplasmsEpithelial-Mesenchymal TransitionGliomaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSerpinsSignal TransductionTOR Serine-Threonine KinasesAnimalsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSerpinsTOR Serine-Threonine Kinasesepithelial‐mesenchymal transitiongliomaPI3K/AKT/mTORSERPINB6

Identifiers

PMID40665565
PMCPMC12264082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.